CONSIDERING FASENRA

JIM — Real FASENRA user and genuine patient story.*

*Results may vary.

FASENRA is an add-on maintenance treatment for patients 12 and older with severe eosinophilic asthma. See more

Not for other eosinophilic conditions or sudden breathing problems.

FASENRA is designed to target and remove eosinophils.
It can help improve breathing and prevent attacks.

The mechanism of action of FASENRA in asthma is not fully understood.

FASENRA is an add-on maintenance treatment for patients aged 12 and older with severe eosinophilic asthma. FASENRA is designed to target cells in your body called eosinophils (e-o-SIN-o-phils), which can be a key cause of severe asthma.

FASENRA is not an inhaler or a steroid. FASENRA is administered only once every 8 weeks after the first 2 months.

First 3 doses given on day 1, week 4, and week 8.

Ask your asthma specialist about FASENRA, the #1 prescribed brand for patients who are new to treatments designed to target eosinophils.§

For new therapy starts based on IQVIA NPA MD & LAAD data for 6 months ending March 2020.
§Comparisons of the number of prescriptions filled does not imply comparable efficacy, safety, or FDA-approved indications.

When added to current asthma treatments, FASENRA has been clinically proven to help:

  • Woman smilingWoman smilingReduce the occurrence of asthma attacks by up to 51%||
  • Woman sitting and stretching Woman sitting and stretchingImprove lung function so you can breathe easier

||In a 48-week clinical trial of FASENRA vs placebo + existing medicines. In a 56-week clinical trial, FASENRA reduced the occurrence of severe asthma attacks by 28% compared with placebo + existing medicines.

Statistical significance in lung function improvement was established at end of treatment. Week 4 results were descriptive only. FASENRA demonstrated greater improvements in lung function compared with placebo at Week 4.

For people who rely on oral steroids, FASENRA can help:

  • View of beautiful landscapeView of beautiful landscapeLower daily oral steroid use by 75%#
  • Man carrying Son Man carrying SonSome people completely stop using oral steroids**

#Median reduction, compared with 25% with placebo and existing medicines in a 28-week clinical trial of FASENRA vs placebo in patients receiving daily steroids + existing medicines.

**Complete reduction of daily steroid use was only in patients taking a daily dose of 12.5 mg or less.

After the first dose, FASENRA can help:

  • Woman in the parkWoman in the parkImprove breathing††
 

††Statistical significance in lung function improvement was established at end of treatment. Week 4 results were descriptive only. FASENRA demonstrated greater improvements in lung function compared with placebo at Week 4.

FASENRA has been studied in a robust clinical trial program in severe eosinophilic asthma. FASENRA worked better than standard asthma treatments alone.

Your results may vary.

Don’t stop your asthma treatments unless your doctor tells you to.

How FASENRA works.

FASENRA works differently from an inhaler or steroid. It is designed to target and remove eosinophils, a key cause of asthma.

Watch how FASENRA works.

FASENRA is designed to target and remove eosinophils, a key cause of asthma. The mechanism of action of FASENRA is not fully understood.

FASENRA is designed to target and remove eosinophils from the blood.

The mechanism of action of FASENRA in asthma is not fully understood.

Take this quiz to see if it might be time for a change in your asthma management plan and talk to your doctor.

If you answered yes to any of these questions, ask your doctor if you could have eosinophilic asthma. If none of your answers were yes, but you are still bothered by your asthma, you should discuss your symptoms with your doctor.

Ask your doctor if FASENRA might be right for you.

A routine blood test can help determine if you have eosinophilic asthma.

If you already have a prescription for FASENRA and have questions, check out the Savings and Support page or the FAQs.

FIND AN ASTHMA SPECIALIST NEAR YOU

FASENRA stories

See how FASENRA has impacted the lives of people living with eosinophilic asthma.

  • Thumbnail of FASENRA patient Brandi

    BRANDI

  • Thumbnail of FASENRA patient Linda

    LINDA

  • Thumbnail of FASENRA patient Barb

    BARB

  • Thumbnail of FASENRA patient Jim

    JIM

  • Thumbnail of FASENRA patient Cheri

    CHERI

  • Thumbnail of FASENRA patient Jon

    JON

Barb discusses her experience after trying FASENRA for her eosinophilic asthma. Watch Jim’s story as he discusses adding FASENRA and managing his eosinophilic asthma. Watch Brandi’s story after taking FASENRA. Linda talks about her journey while taking FASENRA. Cheri talks about her journey while taking FASENRA. Jon talks about his journey while taking FASENRA.

‡‡Results may vary.

  • CHERI 1Life With Asthma

  • CHERI 2My Turning Point

  • CHERI 3Life With FASENRA
  • BRANDI 1Life With Asthma

  • BRANDI 2My Turning Point

  • BRANDI 3Life With FASENRA
  • BARB 1Life With Asthma

  • BARB 2My Turning Point

  • BARB 3Life With FASENRA
  • JIM 1Life With Asthma

  • JIM 2My Turning Point

  • JIM 3Life With FASENRA
  • LINDA 1Life With Asthma

  • LINDA 2My Turning Point

  • LINDA 3Life With FASENRA
  • JON 1Life With Asthma

  • JON 2My Turning Point

  • JON 3Life With FASENRA

‡‡Results may vary.

With FASENRA, you need fewer doses per year and you have convenient injection options.

Your first year on FASENRA vs other treatments§§:

  • 8 DOSES
  • One dose every 8 weeks||||

  • 13 DOSES
  • One dose every 4 weeks

  • 13-26 DOSES
  • One dose every 2-4 weeks

  • 26 DOSES
  • One dose every 2 weeks

§§Dosing comparisons do not imply comparable efficacy, safety, or FDA-approved indications.

||||The first 3 doses are given on day 1, week 4, and week 8.

In 2 clinical trials, injection site reactions occurred at a rate of 2.2% in patients treated with FASENRA vs 1.9% in patients treated with placebo (eg, pain, redness, itching, swelling near where the injection was given).

The majority of physicians and patients preferred an 8-week dosing schedule compared to 2- and 4-week dosing.¶¶

¶¶In a US survey study, 47 adult patients with severe asthma and 25 board-certified specialists (ie, pulmonologists and allergists) were interviewed to understand their perceptions of biologic therapies and preferences in relation to biologic therapy attributes in the treatment of severe, uncontrolled asthma. Key attributes included dosing frequency, number of injections per treatment, delivery route, medication administration, and process required for administration. In this study, 73% of physicians and patients expressed preferences for less frequent administrations.

Your doctor can administer FASENRA or you can do it wherever you are with the FASENRA Pen.##

##After proper training and your healthcare provider's approval

More than 96% of people were able to successfully self-administer the FASENRA Pen***. Talk to your doctor before you self-administer.

***Data from a study designed to assess patient or caregiver reported functionality and reliability of a single-use auto-injector device.

Whichever option you choose, FASENRA uses the smallest needle available of the respiratory biologics.

Find a doctor who specializes in asthma treatments.

Always talk to your doctor if you need medical advice. This information is not a substitute for information you can get from your plan about preferred doctors.

To find a doctor, you can search by ZIP code, and further limit the search to doctors who have been provided information on FASENRA by AstraZeneca. The list of doctors is selected from a nationwide, public database of doctors who have indicated their specialties. This list may not show all the asthma specialists in your area, and it may not have the latest provider information, even though every attempt is made to update the database regularly.

The database is made up of doctors who have been provided information about FASENRA by AstraZeneca, as well as those who have not. Inclusion in this list does not imply a referral, endorsement, or recommendation by AstraZeneca, nor does it imply a doctor’s endorsement of AstraZeneca or any of its products.

When choosing a doctor, verify their acceptance of your health insurance—participation in health networks varies by physician.

Any information you provide is used only to help you find a physician, and will never be shared with third parties. You are responsible for any communications with doctors obtained through this website, and information you share with your doctor is not covered by our Legal Notice or Privacy Notice. You are also bound by laws in your state and federal laws that regulate physician referrals, including, but not limited to, anti-kickback laws, the Stark Law, or state professional practice restrictions.

For access to more in-depth eosinophilic asthma material and helpful FASENRA education, sign up now.

It’s important to be honest with your asthma specialist about your asthma symptoms, so he or she can recommend the right treatment.

Download Discussion Guide

IMPORTANT SAFETY INFORMATION

Do not use FASENRA if you are allergic to benralizumab or any of the ingredients in FASENRA.

Do not use to treat sudden breathing problems.

FASENRA may cause serious side effects, including:

  • allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your FASENRA injection. Allergic reactions can sometimes happen hours or days after you get your injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:

    • swelling of your face, mouth and tongue

    • breathing problems

    • fainting, dizziness, feeling lightheaded (low blood pressure)

    • rash

    • hives

Before using FASENRA, tell your healthcare provider about all of your medical conditions, including if you:

  • are taking oral or inhaled corticosteroid medicines. Do not stop taking your corticosteroid medicines unless instructed by your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine to come back.

  • have a parasitic (helminth) infection.

  • are pregnant or plan to become pregnant. It is not known if FASENRA will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with FASENRA.

    • There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to FASENRA during pregnancy. Healthcare providers can enroll patients or encourage patients to enroll themselves by calling 1-877-311-8972 or visiting www.mothertobaby.org/fasenra.

  • are breastfeeding or plan to breastfeed. It is not known if FASENRA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use FASENRA.

  • are taking prescription and over-the-counter medicines, vitamins, or herbal supplements.

Do not stop taking your other asthma medicines unless instructed to do so by your healthcare provider.

The most common side effects of FASENRA include: headache and sore throat. These are not all the possible side effects of FASENRA.

APPROVED USE

FASENRA is a prescription medicine used with other asthma medicines for the maintenance treatment of asthma in people 12 years and older whose asthma is not controlled with their current asthma medicines. FASENRA helps prevent severe asthma attacks (exacerbations) and may improve your breathing. Medicines such as FASENRA reduce blood eosinophils. Eosinophils are a type of white blood cell that may contribute to your asthma.

FASENRA is not used to treat other problems caused by eosinophils and is not used to treat sudden breathing problems. Tell your healthcare provider if your asthma does not get better or if it gets worse after you start treatment with FASENRA.

It is not known if FASENRA is safe and effective in children under 12 years of age.

Please see accompanying full Prescribing Information including Patient Information and Instructions for Use.

You may report side effects related to AstraZeneca products by clicking here.